The Uninvited: Sanjay Kaul removed from prasugrel’s FDA advisory panel 5

CardioBrief has learned from multiple sources that Sanjay Kaul will not be a member of the FDA advisory panel on Tuesday’s hearing to evaluate prasugrel. Kaul has been a sharp critic of recent drug trials, and has raised public concerns about prasugrel and other cardiovascular agents in recent years. Kaul’s name appeared on the FDA roster posted on the FDA website last Friday. Although his name still appeared on the document at the time of this posting, Kaul was removed late last week from the committee for having an intellectual conflict of interest, though it is unclear exactly what this means or what it implies. Certainly the FDA had to have known that Kaul was an outspoken critic– just google “Kaul and prasugrel” to see what I mean. So this raises the question: what prompted this last minute dramatic move on the part of the FDA?


  1. Pingback: Health Blog : Prasugrel Review Proceeds Without Key Safety Experts

  2. Pingback: Editorial: prasugrel and FDA incompetence « CardioBrief

  3. Pingback: FDA provides “explanation” for Sanjay Kaul’s absence « CardioBrief

  4. Pingback: Chronology of Prasugrel Controversy « CardioBrief

  5. Pingback: Oops, She Did It Again! FDA Disinvites Another Advisor « CardioBrief

What do you think?

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s